Study of the Glutaminase Inhibitor CB-839 in Leukemia

Exclusion Criteria

• •Any other current malignancy
• •Patients with acute promyelocytic leukemia (APL)
• •Treatment with an unapproved, investigational agent within 21 days of the first dose of study drug
• •Allogeneic hematopoietic stem cell transplant or Donor Lymphocyte Infusion within 90 days prior to to the first dose of study drug
• •Active GVHD
• •Unable to receive medications by mouth
• •Major surgery within 28 days before Cycle 1 Day 1
• •Uncontrolled, active infection; patients who are known to have HIV infection/ seropositivity, Hepatitis A, B, or C, or CMV reactivation
• •Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days prior to Day 1
• •Refractory nausea and vomiting or other situation that may preclude adequate absorption
• •Conditions that could interfere with treatment and procedures